Freshfields Advised Cartography Biosciences On Its Collaboration And License Agreement With Pfizer For The Discovery Of Tumor Selective Antigens

Freshfields Advised Cartography Biosciences On Its Collaboration And License Agreement With Pfizer For The Discovery Of Tumor Selective Antigens

Freshfields advised Cartography Biosciences, Inc., a biotechnology company focused on advancing antibody-based cancer therapies, on its agreement with Pfizer pursuant to which Pfizer may option rights to exploit multiple tumor-selective antigens that Cartography will identify and validate through its proprietary ATLAS and SUMMIT discovery platforms.

Under the terms of the agreement, Cartography is eligible to receive up to $65 million in upfront, near-term milestone, and option exercise payments, and the agreement’s potential total deal value may exceed $850 million if all options are exercised, with Cartography being eligible to receive future development, regulatory, and commercial milestones and tiered royalties on net sales for any programs Pfizer advances under the collaboration.

The Freshfields team was led by Vinita Kailasanath (Partner), and included Jake Silvers (Senior Associate), and Juliana Zhang (Associate).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.